This is part 2 of our newsletter discussing GLP-1 agonists (GLP-1A) with opportunities for innovation in the food industry.
Last month, we talked about the importance of addressing nutrient needs for those who use GLP-1A and ingredients that may support endogenous secretion of GLP-1 and weight maintenance. We focused on the need for prepackaged, portion-controlled meals and snacks that deliver needed protein, fiber, healthy fats, and other nutrients of concern. Food and beverage companies are starting to enter the market.
Today, we explore harnessing the power of personalization to optimize outcomes for GLP-1A users.
What We Know About GLP-1A Response Variability
A wealth of innovation opportunities exists in better understanding individual differences in GLP-1A user’s biology, behaviors, and side effects. There is considerable variability in individual responses to GLP-1As regarding the amount and type of weight loss and the type and severity of side effects experienced.
Individual responses to GLP-1As can influence appetite regulation, glucose control, and nutrient absorption. Differences in endogenous GLP-1, gender, genetics, metabolism, lifestyle, and eating habits may determine why some individuals are more responsive to treatment than others.
Men, for example, who typically have more lean mass than women, may experience greater fat-free mass and skeletal muscle loss when taking GLP-1As. Differences in muscle loss can be further influenced by age, nutrition, exercise, and insulin sensitivity. High protein diets may preserve lean body mass with weight loss.
Another factor that seems to influence individual success is certain behaviors. Emotional eaters (i.e., people who overeat in response to negative emotions) treated with GLP-1As maintain stronger brain responses to pictures of food and seem to be more vulnerable to cravings. In contrast, restrained eaters (i.e., those who mindfully reduce food intake to control body weight) seem to show increased sensitivity to GLP-1A-induced changes in the brain.
This diversity underscores the opportunity for research to better understand differences in biology and behavior to develop personalized products and services tailored to each user's unique needs during GLP-1A use. At the same time, there are opportunities to address patients' needs today.
Where We See Immediate Opportunities for Product Development
One area is helping GLP-1A users manage and recover from side effects, which 40-70% of patients experience. Clinical recommendations have been developed to help counter these side effects, which can shape innovation opportunities.
In summary, as the use of GLP-1As grows, there are significant opportunities for innovation in the food industry. Your company can create targeted solutions supporting health outcomes and behavior change by addressing users’ unique challenges and tailoring products to meet their needs. This approach will enhance the user experience and open the door to new product development and business growth.